Maralyn Druce

Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Year:

2026

While most individuals with familial medullary thyroid carcinoma (fMTC) carry RET mutations, in some instances the causative mutations remain unknown. We studied two related families with RET-negative fMTC in 21 affected individuals through linkage analysis, exome/genome sequencing, and high-density array comparative genomic hybridization. We identified a novel heterozygous 40kb intragenic SLC30A9 deletion which segregated with the disease in all affected individuals. The mutant transcript escaped nonsense-mediated decay and resulted in the production of N-terminally truncated proteins via translation reinitiation from in-frame AUG codons located downstream of the deletion. These proteins showed increased stability and their expression in an MTC cell line increased cell proliferation and clonogenic capacity, supporting an oncogenic role. These findings expand the genetic background of fMTC beyond RET mutations and implicate translation reinitiation in the etiology of cancer susceptibility syndromes secondary to structural genomic variants.

Year:

2026

Objective This review seeks to provide endocrine clinicians with a comprehensive analysis of breast cancer risk, diagnostic modalities and management strategies in women with endocrine disorders, with particular emphasis on the influence of metabolic factors such as diabetes and obesity, and the role of Menopausal Hormone Therapy (MHT). Design The review examines a spectrum of endocrine disorders commonly encountered in clinical practice, including Multiple Endocrine Neoplasia Types 1 (MEN1), 2 (MEN2) and 4 (MEN4), Von Hippel‐Lindau syndrome (VHL), Pheochromocytoma and Paraganglioma (PPGL), Acromegaly, Hyperprolactinaemia, Polycystic Ovary Syndrome (PCOS), Congenital Adrenal Hyperplasia (CAH), Turner Syndrome, alongside metabolic conditions such as diabetes and obesity and the effects of MHT. The review critically appraises each disorder's association with breast cancer risk, screening implications and therapeutic management. Patients This analysis focuses on women with the aforementioned endocrine and metabolic disorders, assessing their specific breast cancer risk profiles, informed by the latest clinical evidence and molecular insights. Measurements The review comprehensively evaluates current evidence‐based approaches to screening, diagnostic accuracy and treatment in this patient cohort. Emphasis is placed on the metabolic derangements, hormonal influences and genetic predispositions that modulate breast cancer risk, providing disorder‐specific recommendations for individualised care. Results The findings indicate a significantly elevated breast cancer risk in patients with MEN1, necessitating early initiation of MRI screening by age 40. In MEN2, emerging evidence suggests that combining RET inhibitors with endocrine therapy may yield clinical benefits, although further research is needed to validate this approach. The breast cancer risk associated with MEN4 and VHL syndromes, while documented, remains less well‐characterised, requiring further investigation. Diabetes and obesity are confirmed as major modifiable risk factors, particularly in postmenopausal women, where hyperinsulinemia and metabolic dysfunction contribute to increased incidence and poorer outcomes, notably in triple‐negative breast cancer (TNBC). The role of MHT, particularly combined oestrogen‐progestogen therapy, is strongly associated with increased breast cancer risk, particularly for hormone receptor‐positive malignancies, necessitating cautious use and personalised treatment planning. In contrast, oestrogen‐only MHT appears to confer a reduced risk in women post‐hysterectomy. For patients with PCOS, CAH and Turner Syndrome, while definitive evidence of elevated breast cancer risk is lacking, individualised screening strategies and careful hormone therapy management remain essential due to the complex interplay of hormonal and metabolic factors. Conclusions The review highlights the need for personalised breast cancer screening and management protocols in women with endocrine and metabolic disorders. For high‐risk groups such as MEN1 patients, early initiation of MRI screening is warranted. In women with diabetes and obesity, targeted interventions addressing hyperinsulinemia and metabolic dysfunction are critical to mitigating their increased cancer risk. The association between MHT and breast cancer underscores the importance of individualised risk stratification in hormone therapy administration, particularly in women with predisposing genetic or endocrine conditions. Enhanced surveillance tailored to the unique risk profiles of endocrine disorder patients will facilitate early detection and improve clinical outcomes. However, further large‐scale studies are necessary to refine these associations and develop robust, evidence‐based guidelines.

Year:

2025

Objective To investigate the impact of musculoskeletal (MSK)‐related symptoms on the quality of life of patients with multiple endocrine neoplasia Type 2b (MEN2B). Design An online survey was distributed by the Association for Multiple Endocrine Neoplasia Disorders (AMEND) to their members and worldwide via a social media group for MEN2B patients. Methods The survey consisted of a detailed questionnaire analysing the MSK‐related symptoms and structural deformities of MEN2B patients and their impact on patient's lives. Participants Forty‐eight participants completed the survey. Results Participants reported several musculoskeletal complaints; the most prevalent being musculoskeletal weakness at 73% ( n = 35) and pain 58% ( n = 28). The median pain score was 7 (interquartile range [IQR]: 5–8) and the frequency of pain was daily in 44% ( n = 15) and constant in 21% ( n = 7). Structural complaints were common with 63% ( n = 30) stating their physique was ‘different' and 40% ( n = 19) describing marfanoid body features. Spinal curvature and foot deformities were the commonest structural abnormalities with scoliosis 70% ( n = 16) and pes cavus 63% ( n = 22) prevailing. Dental problems were mentioned by 69% ( n = 33) with interdental spacing being the most common complaint at 61% ( n = 20). The musculoskeletal symptoms of MEN2B had a median impact of 6 (IQR: 3–9) on quality of life (QOL) with structural deformities 53% ( n = 18) and pain 26% ( n = 9) listed as having the highest impact. Poor MSK health affected exercise, work and mobility. Conclusions We report a high prevalence of musculoskeletal‐related complaints in MEN2B which significantly affects QOL. This suggests a need to provide better holistic care including a multidisciplinary team with physiotherapist, orthopaedic and dental specialist input.

Year:

2022

Collaborators (17)

Federica Begalli

Lecturer in Endocrinology

Queen Mary University of London

UNITED KINGDOM
View details

William Foulkes

Full Professor

McGill University

CANADA
View details

Marton Doleschall

senior scientist

Semmelweis University

HUNGARY
View details

Horia Constantin Stanescu

University College London

UNITED KINGDOM
View details

Michael Witcher

Associate Professor

Lady Davis Institute for Medical Research

CANADA
View details

Jolanta Krajewska

Associate Professor

Maria Sklodowska-Curie Institute - Oncology Center Gliwice Branch

POLAND
View details

Anne Barlier

Aix-Marseille University

FRANCE
View details

Maria Alevizaki

Professor of Endocrinology

National and Kapodistrian University of Athens

GREECE
View details

Sabrina Chiloiro

Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia

ITALY
View details

Márta Korbonits

Deputy Director of the William Harvey Research Institute

Queen Mary University of London

UNITED KINGDOM
View details

Donato Iacovazzo

NIHR Clinical Lecturer

Queen Mary University of London

UNITED KINGDOM
View details

Malgorzata Oczko-Wojciechowska

Head of Department/Ph.D

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND
View details

Jes Mathiesen

University of Southern Denmark

DENMARK
View details

R Mihai

Oxford University Hospitals NHS Foundation Trust

UNITED KINGDOM
View details

Suvi Savola

Head of Oncogenetics

MRC-Holland

NETHERLANDS
View details

James R. Lupski

-

UNITED STATES
View details

Miklós Tóth

professor

Semmelweis University

HUNGARY
View details